Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.Here is the latest financial fact sheet of Torrent Pharma. For more details, see the Torrent Pharma quarterly results and Torrent Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
% ch | % | 0.3 |
No. of shares | m | 169.26 |
% ch week | % | -0.9 |
% ch 1-mth | % | -6.1 |
% ch 12-mth | % | 25.3 |
52 week H/L | Rs | 1,960.0/1,223.8 |
No. of Mths Year Ending |
12 Mar-14* |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
5-Yr Chart Click to enlarge
|
---|
TORRENT PHARMA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 578 | 1,232 | 1,720 | 1,768 | 1,550 | |
Low | Rs | 334 | 523 | 1,134 | 1,186 | 1,144 | |
Sales per share (Unadj.) | Rs | 247.3 | 275.0 | 394.5 | 346.1 | 354.7 | |
Earnings per share (Unadj.) | Rs | 39.2 | 44.4 | 102.4 | 55.2 | 40.1 | |
Diluted earnings per share | Rs | 39.2 | 44.4 | 102.4 | 55.2 | 40.1 | |
Cash flow per share (Unadj.) | Rs | 44.4 | 55.6 | 116.5 | 73.3 | 64.2 | |
Dividends per share (Unadj.) | Rs | 10.00 | 11.25 | 40.00 | 14.00 | 14.00 | |
Adj. dividends per share | Rs | 10.00 | 11.25 | 39.99 | 14.00 | 14.00 | |
Dividend yield (eoy) | % | 2.2 | 1.3 | 2.8 | 0.9 | 1.0 | |
Book value per share (Unadj.) | Rs | 112.4 | 156.2 | 206.5 | 257.1 | 273.1 | |
Adj. book value per share | Rs | 112.4 | 156.1 | 206.4 | 257.0 | 273.1 | |
Shares outstanding (eoy) | m | 169.22 | 169.22 | 169.22 | 169.22 | 169.22 | |
Bonus/Rights/Conversions | B1:1 | - | - | - | - | ||
Price / Sales ratio | x | 1.8 | 3.2 | 3.6 | 4.3 | 3.8 | |
Avg P/E ratio | x | 11.6 | 19.8 | 13.9 | 26.8 | 33.6 | |
P/CF ratio (eoy) | x | 10.3 | 15.8 | 12.3 | 20.1 | 21.0 | |
Price / Book Value ratio | x | 4.1 | 5.6 | 6.9 | 5.7 | 4.9 | |
Dividend payout | % | 25.5 | 25.4 | 39.1 | 25.4 | 34.9 | |
Avg Mkt Cap | Rs m | 77,190 | 148,465 | 241,435 | 249,887 | 227,897 | |
No. of employees | `000 | 9.5 | 11.0 | 10.9 | 11.8 | 14.7 | |
Total wages/salary | Rs m | 7,411 | 8,418 | 8,424 | 9,934 | 11,353 | |
Avg. sales/employee | Rs Th | 4,386.5 | 4,212.4 | 6,129.6 | 4,971.5 | 4,083.0 | |
Avg. wages/employee | Rs Th | 776.8 | 762.0 | 773.4 | 843.2 | 772.3 | |
Avg. net profit/employee | Rs Th | 695.9 | 679.8 | 1,591.3 | 792.4 | 461.3 |
TORRENT PHARMA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 41,847 | 46,535 | 66,764 | 58,569 | 60,021 | |
Other income | Rs m | 381 | 2,856 | 2,256 | 2,233 | 2,988 | |
Total revenues | Rs m | 42,229 | 49,390 | 69,020 | 60,802 | 63,009 | |
Gross profit | Rs m | 9,515 | 10,202 | 27,330 | 13,773 | 13,493 | |
Depreciation | Rs m | 870 | 1,907 | 2,376 | 3,069 | 4,086 | |
Interest | Rs m | 586 | 1,752 | 1,840 | 2,056 | 3,085 | |
Profit before tax | Rs m | 8,440 | 9,398 | 25,371 | 10,881 | 9,310 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | -1,936 | 0 | 0 | |
Tax | Rs m | 1,801 | 1,888 | 6,102 | 1,545 | 2,529 | |
Profit after tax | Rs m | 6,639 | 7,509 | 17,333 | 9,336 | 6,781 | |
Gross profit margin | % | 22.7 | 21.9 | 40.9 | 23.5 | 22.5 | |
Effective tax rate | % | 21.3 | 20.1 | 24.1 | 14.2 | 27.2 | |
Net profit margin | % | 15.9 | 16.1 | 26.0 | 15.9 | 11.3 |
TORRENT PHARMA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 34,045 | 40,983 | 46,882 | 48,794 | 52,623 | |
Current liabilities | Rs m | 21,746 | 27,046 | 32,855 | 27,383 | 52,022 | |
Net working cap to sales | % | 29.4 | 30.0 | 21.0 | 36.6 | 1.0 | |
Current ratio | x | 1.6 | 1.5 | 1.4 | 1.8 | 1.0 | |
Inventory Days | Days | 88 | 84 | 74 | 97 | 120 | |
Debtors Days | Days | 96 | 125 | 79 | 59 | 76 | |
Net fixed assets | Rs m | 14,095 | 34,720 | 39,007 | 42,079 | 85,016 | |
Share capital | Rs m | 846 | 846 | 846 | 846 | 846 | |
"Free" reserves | Rs m | 17,272 | 25,583 | 34,095 | 42,655 | 45,376 | |
Net worth | Rs m | 19,024 | 26,430 | 34,941 | 43,501 | 46,222 | |
Long term debt | Rs m | 7,445 | 21,729 | 18,501 | 22,408 | 41,115 | |
Total assets | Rs m | 50,698 | 79,641 | 90,579 | 97,021 | 142,432 | |
Interest coverage | x | 15.4 | 6.4 | 14.8 | 6.3 | 4.0 | |
Debt to equity ratio | x | 0.4 | 0.8 | 0.5 | 0.5 | 0.9 | |
Sales to assets ratio | x | 0.8 | 0.6 | 0.7 | 0.6 | 0.4 | |
Return on assets | % | 14.3 | 11.6 | 21.2 | 11.7 | 6.9 | |
Return on equity | % | 34.9 | 28.4 | 49.6 | 21.5 | 14.7 | |
Return on capital | % | 34.1 | 23.2 | 47.3 | 19.6 | 14.2 | |
Exports to sales | % | 37.4 | 30.4 | 43.3 | 0 | 0 | |
Imports to sales | % | 8.2 | 6.0 | 6.9 | 0 | 0 | |
Exports (fob) | Rs m | 15,665 | 14,136 | 28,934 | 0 | 0 | |
Imports (cif) | Rs m | 3,416 | 2,801 | 4,584 | 0 | 0 | |
Fx inflow | Rs m | 16,862 | 14,265 | 29,185 | 20,066 | 14,580 | |
Fx outflow | Rs m | 5,196 | 5,184 | 6,021 | 5,304 | 3,600 | |
Net fx | Rs m | 11,666 | 9,081 | 23,165 | 14,762 | 10,980 |
TORRENT PHARMA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 5,994 | 8,102 | 27,421 | 10,088 | 8,942 | |
From Investments | Rs m | -3,558 | -21,623 | -8,379 | -7,869 | -47,070 | |
From Financial Activity | Rs m | 864 | 12,123 | -14,352 | -1,929 | 34,174 | |
Net Cashflow | Rs m | 3,300 | -1,399 | 4,375 | 177 | -3,655 |
Share Holding
|
Company Information
|
CHM: Sudhir Mehta | COMP SEC: Mahesh Agarwal | YEAR OF INC: 1973 | BSE CODE: 500420 | FV (Rs): 5 | DIV YIELD (%): 0.8 |
More Pharmaceuticals Company Fact Sheets: VENUS REMEDIES SUN PHARMA NATCO PHARMA ALEMBIC LTD STRIDES PHARMA SCIENCE
Compare TORRENT PHARMA With: VENUS REMEDIES SUN PHARMA NATCO PHARMA ALEMBIC LTD STRIDES PHARMA SCIENCE
Compare TORRENT PHARMA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
| |
The stock markets are very volatile these days. As the Tanushree Bannerjee, the co-head of research here at Equitymaster puts it, stock markets are two-faced.
For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Should you subscribe to the IPO of Shalby Ltd?
Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsTanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.
Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...
A roundtable on the 18th of January 2019 had investors with billions of dollars of investment kitty.
This is the trick to following super investors and not losing money.
While selecting good businesses is relatively easy task in a bearish phase, where most people fail is in having enough patience to hold the quality stocks until recovery.
More
| |